UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 15, 2016

CRYOLIFE, INC.
(Exact name of registrant as specified in its charter)

Florida	**1-13165**	**59-2417093**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144
(Address of principal executive office) (zip code)
Registrant's telephone number, including area code: (770) 419-3355

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

CryoLife, Inc. (the "Company") is furnishing the presentation slides attached as Exhibit 99.1 to this Current Report, which the Company will present at meeting of Atlanta Unlimited Investments LLC on February 15, 2016 and may from time to time use in other conferences or conversations with investors and analysts. This presentation will also be posted on the investor relations portion of the Company's website, www.cryolife.com, during the time period when it is used by the Company.

The information furnished in this Current Report and the exhibit attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1*	CryoLife, Inc. Investor Presentation, dated February 15, 2016

* Furnished herewith, not filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CRYOLIFE, INC.

By: /s/ D. Ashley Lee

Name: D. Ashley Lee

Title: Executive Vice President, Chief Operating Officer, Chief Financial Officer and Treasurer

Date: February 16, 2016

Exhibit 99.1


Pat Mackin
President & CEO
February 15, 2016
CryoLife
Life Restoring Technologies

Forward Looking Statement

Statements made in this presentation that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include those regarding CryoLife's ability to become a leader in providing unique and differentiated technologies and solutions for patients with structural heart disease that will improve clinical outcomes as well as reduce overall cost to the healthcare system; the ability of our product portfolio to drive growth; the ability of the On-X acquisition to accelerate growth and expand gross margins; the expected growth of the market for our aortic heart valves due to demographics and device adoption; our expectations that our 2016 revenue and gross margins for BioGlue sales in France will improve from 2014 as a result of our move to a direct sales model in France; our expectation that there will be additional upside for our product sales in France as we leverage direct sales of our full product portfolio in France; our ability to expand our sales of BioGlue in Japan as a result of receiving in 2015 an expanded indication for BioGlue for use in thoracic aneurysm, Bentall & LVAD procedures; our expectations regarding our ability to execute on our clinical trial for BioGlue in China and the timeline for that clinical trial; our expectations regarding the ability of the On-X transaction to enhance our growth profile, increase opportunities for cross selling, drive margin expansion, provide CryoLife with a new addressable market opportunity of $220MM, generate highly attractive margins, facilitate increased adoption of On-X portfolio penetration, enhance and leverage our existing direct sales organization, and strengthen our strategic focus on aortic and mitral valve repair and replacement surgery; the ability of the INR indication for the On-X valve of 1.5 to 2.0, to be a significant differentiator, distinct competitive advantage and catalyst for us to achieve market leadership in the mechanical heart valve market; our belief that compelling clinical data regarding the On-X valve supports future growth; our belief regarding the ability to increase physician familiarity with the On-X heart valve and increase the percent of hospitals stocking the On-X heart valve; our belief in our ability to increase revenues through differentiated products such as PhotoFix; our expectations regarding our ability to execute on the PerClot clinical trial and our belief that we can obtain PMA approval for PerClot in the US by 2019; the anticipated benefits for our business development program, including double digit CAGR in adjusted non-GAAP earnings from 2016 – 2020; and our beliefs regarding our expectations for financial performance in 2016. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2014 and our subsequent filings with the SEC, including our Form 10-K for year ended December 31, 2015. CryoLife does not undertake to update its forward-looking statements.

My Background (1988-2015)

1988-1991	1991-2002	2002-2014	2014-Present
U.S.ARMY	genzyme	Medtronic	CryoLife® Life Restoring Technologies®











CryoLife- Cardiovascular Technology Business



CryoLife Vision Slide

Become a leader in providing unique and differentiated technologies and solutions for patients with structural heart disease that will improve clinical outcomes as well as reduce the overall cost to the healthcare system

Investment Rationale

- Proven Leadership
- Established Product Portfolio Driving Profitable Growth
- On-X Acquisition Accelerates Growth and Margin Expansion
- Highly Experienced Direct Sales Organization
- Active Business Development Program

Recent Additions to Leadership Team

PAT MACKIN, Chairman, President & Chief Executive Officer
20 + Years Experience
Previous Companies: Medtronic, Genzyme, Deknatel/Snowden-Pencer
Education: B.S. United States Military Academy at West Point and M.B.A. Kellogg Graduate School of Management at Northwestern University

JEAN HOLLOWAY, Senior Vice President, General Counsel & Corporate Secretary
30 + Years Experience
Previous Companies: C.R Bard, Medtronic, Boston Scientific, Guidant Corporation
Education: J.D./M.B.A. (cum laude) from the University of Chicago, and two undergraduate degrees from Yale University

JOHN DAVIS, Senior Vice President, Global Sales & Marketing
25 + Years Experience
Previous Companies: CorMatrix Cardiovascular, St. Jude, Medtronic
Education: Bachelor of Arts, English from Western Carolina University

BILL MATTHEWS, Senior Vice President, Operations, Quality and Regulatory
30 + Years Experience
Previous Companies: BioDevice Solutions, Fresenius Medical Care, Cardinal Health's Viasys Healthcare, Beiersdorf AG
Education: Bachelor of Science in Chemistry from St. Peter's University and Business Administration programs from Rutgers University and Fairleigh Dickson University

Growing Annual Revenues

CAGR '10-'15: 4.7%

Mix Shift to Higher Margin Medical Device Products

	2010	2011	2012	2013	2014	2015
Tissue	59.7	59.8	63.6	64.5	62.8	62.8
Products	56.4	59.4	67.5	76.2	81.9	83.1
Total*	**116.1**	**119.2**	**131.1**	**140.7**	**144.7**	**145.9**

Product CAGR '10-'15 8.1%

Tissue CAGR '10-'15 1.0%

*Excludes grant revenue

CryoLife Major Product Lines

Allograft Tissues

37% of Revenue

On-X
Heart Valve

20% of Revenue

BioGlue®
Surgical Adhesive

35% of Revenue

Source: Revenue calculated as pro forma 2015

CryoLife Products- Cryopreserved Tissue

Cryopreserved Tissue: Five-Year Tissue Revenue

REVENUE



	2010	2011	2012	2013	2014	2015
Revenue	$59.7	$59.8	$63.6	$64.5	$62.8	$62.8

BUSINESS MIX



PRODUCTS


Pulmonary valve


Aortic valve


Saphenous vein


Cardiac patch

Pulmonary Valve Homografts

CryoValve® SG Pulmonary Valves

SynerGraft® decellularized technology

- Seven published papers with >2,000 patient years follow up
- 10 year actuarial freedom from explant = 93%[1]
- Over 28,000 pulmonary valves implanted since 1984[2]



US Pulmonary Valve Replacement Market:
2,300 procedures

Market Size = $24M
2% CAGR



US Clinical Effectiveness[1]

1 CryoLife, Inc. Post-clearance Study (CSG801.002), data on file; 2. CryoLife, Inc. data on file

Note: Market procedures, share, size, and CAGR are approximate annual U.S. numbers based on actual CryoLife data and market reports, including LSI, IData and IMS.

Aortic Valve Homografts

CryoValve® Aortic Heart Valves

Society of Thoracic Surgeons recommendation[1]

Class I - Homograft replacement of the aortic root should be considered for patients with extensive active endocarditic destruction of the aortic annulus. **(Level of evidence B)**

Class IIa - Homograft replacement of the aortic valve can be considered for patients with endocarditis without annular destruction, especially when the potential for reinfection is elevated. **(Level of evidence B)**

95% freedom from recurrent endocarditis at 10 years[2,3]

Growing market due to demographics and device adoption (TAVR)



US Aortic Valve Replacement due to Endocarditis Market[5]: 3,200 procedures

Market Size = $22.5M
9% CAGR



US Incidence of Endocarditis[4]

1. Svensson LG, et al. Ann Thorac Surg 2013; 95:1491-1505; 2. Doty JR, et al. J Thorac Surg 1998; 115:371-380; 3.Sabik JF, et al. Ann Thorac Surg 2002; 74:660-669; 4. Byrne JG, et al. Ann Thorac Surg 2011;91:2012-2019; 5.Estimated number of endocarditis cases based on figures from "Infective Endocarditis in the U.S., 1998-2009: A Nationwide Study" by Bor DH, et al. PLoS ONE, published 3/20/2013 and Cleveland Clinic estimates that ~30% of diagnosed infective endocarditis require surgery, of those, the majority are aortic (vs mitral or pulmonary) valve."

Note: Market procedures, share, size, and CAGR are approximate annual U.S. numbers based on actual CryoLife data, clinical publications, and market reports, including LSI, IData and IMS.

CryoLife Products- BioGlue Sealant

BioGlue Surgical Sealant

REVENUE



	2010	2011	2012	2013	2014	2015
Revenue	$47.3	$49.3	$53.0	$57.6	$61.7	$59.0

BioGlue Indications



Global Expansion- Direct in France

Direct in France

- No revenue from France January-September 2015 as distributor sold off inventory
- June 22nd announced agreement with French distributor to take business direct on October 1st, 2015
- 2014 revenue of BioGlue and PerClot was $3 million
- Expect 2016 revenue and gross margin will improve from 2014 as we sell directly to hospital customers
- Additional upside as we leverage direct sales of the full product portfolio

Indication Expansion- Japan BioGlue

Japan BioGlue

- Current indication only for aortic dissection (5,500 procedures)
- Expanded approval for thoracic aneurysm, Bentall & LVAD (5,500 procedures)
- Doubles existing market from $5 million to $10 million
- PMDA approval July 2015
- MHLW reimbursement September 2015





Global Expansion- BioGlue China

BioGlue in China

- **Significant market opportunity: >40,000 aortic surgeries**
- **Estimated Timeline**
  - Clinical trial design developed in 2015
  - Standards testing completed, clinical trial approval by CFDA, and Ethics Committee submissions/approvals in 2016
  - Enroll trial and collect follow-up in 2017 (3 month follow-up)
  - 1 year CFDA approval in 2018

CryoLife Products - On-X Valves

REVENUE

	2010	2011	2012	2013	2014	2015
Revenue	$20.4	$23.1	$25.3	$29.0	$33.1	$33.3

BUSINESS MIX



PRODUCTS


On-X Aortic Valve


On-X Mitral Valve


On-X Ascending Aortic Prosthesis (AAP)


OEM

CryoLife® Life Restoring Technologies® + On-X life technologies, inc.™

Transformational acquisition that enhances our growth profile, increases opportunities for cross-selling and drives margin expansion

- Provides CryoLife with new addressable market opportunity of ~$220MM
- Acquired products generate highly attractive margins
- Facilitates increased adoption of On-X portfolio penetration
- Enhances and leverages existing CryoLife direct sales organization
- Strengthens our strategic focus on aortic and mitral valve repair and replacement surgery

The combination of On-X best-in-class mechanical valve technology supported by extensive clinical data are key growth drivers

On-X has the **only** FDA approved mechanical aortic valve labeled for an INR of just 1.5 to 2.0, substantially reducing a patient's bleeding risk - a significant differentiator and distinct competitive advantage

Worldwide Mechanical Valve Market



	2014	2015	2016	2017	2018	2019	2020
US	82	79	77	75	74	73	71
ROW	139	141	143	146	150	154	160
Total	221	220	220	221	224	227	231

Source: Millennium Research Group

Best-in-Class Mechanical Valve Technology

Aortic Valve Flow Comparison

ON-X VALVE

ON-X VALVE FLOW



TRADITIONAL MECHANICAL VALVE FLOW



Best-in-Class Mechanical Valve Technology

Microstructure Comparison

ON-X VALVE
Silicon-free On-X® carbon



MARKET-LEADING COMPETITOR



Steady Growth With Modest Sales Support

The Power of On-X Technology



Source: Millennium Research Group

Surgeon Prioritized Criteria for Selecting Valves



Late Outcomes with Tissue Valves Vary by Age

Patients <65 years old start to receive explants at year 7 and 70% are explanted by year 12

Late Outcomes for Aortic Valve Replacement With the Carpentier-Edwards Pericardial Bioprosthesis: Up to 17-Year Follow-Up in 1,000 Patients

R. Scott McClure, MD, SM, Narendren Narayanasamy, MD, Esther Wiegerinck, BA, Stuart Lipsitz, ScD, Ann Maloney, BA, John G. Byrne, MD, Sary F. Aranki, MD, Gregory S. Couper, MD, and Lawrence H. Cohn, MD

Division of Cardiac Surgery, Brigham and Women's Hospital, and Center for Surgery and Public Health, Harvard Medical School, Boston, Massachusetts



Fig 2. Age-stratified freedom from structural valve deterioration necessitating reoperation using the Carpentier-Edwards pericardial aortic bioprosthesis. (Blue line = age less than 65 years; red line = age 65 to 75 years; green line = age 75 years or more.)

Significant Recent Developments

PROACT trial results and recent FDA approval of 1.5 to 2.0 INR are catalysts for On-X valve to achieve market leadership



Source: PMA P000037 supplement 30, approval date April 01, 2015

Clinical Data Supports Future Growth

Data shows an opportunity to switch future patients from tissue



Source: Puskas et al., J Thorac Cardiovasc Surg 2014;147:1202-11

Clinical Data Supports Future Growth

On-X has the only FDA approved mechanical aortic valve requiring an INR of just 1.5 to 2.0, substantially reducing a patient's bleeding risk — a significant differentiator and distinct competitive advantage

65%
Reduction in bleeding

EVENT	CONTROL (ptyr=878.6) (2.0-3.0) N	CONTROL RATE (%/ptyr)	TEST (ptyr=766.2) (1.5-2.0) N	TEST RATE (%/ptyr)	RATE RATIO (test/control)	95% CI	P-VALUE
Major Bleed	**34**	**3.87**	**12**	**1.57**	**0.40**	**0.21-0.78**	**0.007**
Cerebral Bleed	4	0.46	1	0.13	0.29	0.03-2.56	0.264
Minor Bleed	**35**	**3.98**	**9**	**1.17**	**0.29**	**0.14-0.61**	**0.001**
Total Bleed	**69**	**7.85**	**21**	**2.74**	**0.35**	**0.21-1.57**	**<0.001**
Ischemic Stroke	7	0.80	6	0.78	0.98	0.33-2.92	0.975
TIA	7	0.80	11	1.44	1.80	0.70-4.65	0.223
Neurologic Event	14	1.59	17	2.22	1.39	0.69-2.82	0.359
Peripheral TE	1	0.11	4	0.52	4.59	0.51-41.04	0.173
Thrombosis	2	0.23	2	0.26	1.15	0.16-8.14	0.891
Major Bleed, TE, Thrombosis (AATS Guideline)	51	5.80	35	4.57	0.79	0.51-1.21	0.275
Primary Endpoint	**86**	**9.79**	**44**	**5.74**	**0.59**	**0.41-0.84**	**0.004**
Sudden Death	3	0.34	3	0.39	1.15	0.23-5.68	0.867
Valve-related Death	3	0.34	2	0.26	0.76	0.13-4.57	0.769
Total Mortality	16	1.82	12	1.57	0.86	0.41-1.82	0.693

Source: PMA P000037 supplement 30, approval date April 01, 2015

Surgeon Question

Do you think the PROACT results showing 65% reduction in bleeding are compelling enough to get surgeons to change from their current mechanical valve to On-X?

83% Responded Yes N=35


WSJ http://www.wsj.com/articles/clot-risk-is-seen-in-some-hear
MSN.com - Hotmail, O...
CryoLife, Providing Stat...
CNN - Breaking News, ...
WSJ Clot Risk Is Seen in S...
File Edit View Favorites Tools Help
DOW JONES, A NEWS CORP COMPANY
DJIA Futures 15772 1.03% S&P 500 F 1846.25 1.19% Stoxx 600 309.45 1.93% U.S. 10 Yr -9/32 Yield 1.692% Crude Oil 27.60 5.30% Euro 1.1280 -0.39%
THE WALL STREET JOURNAL.
Subscribe Now | Sign In
SPECIAL OFFER: JOIN NOW
Home World U.S. Politics Economy Business Tech Markets Opinion Arts Life Real Estate
Search
Clinton, Sanders Clash Over Cost of Plans
Gravitational Waves Detected, Verifying Part of Einstein Theory
Veterans' Wait After Trump Fundraiser Shows Hurdles ...
Oregon Standoff Ends as Last 4 Occupiers Surrender
YOU ARE READING A PREVIEW OF A PAID ARTICLE. SUBSCRIBE NOW TO GET MORE GREAT CONTENT.
U.S. | GENERAL NEWS
Clot Risk Is Seen in Some Heart Valves
The FDA and cardiologists warn about animal tissue devices that have been widely used for decades
WSJ+
DISCOVER MORE
THE WALL STREET JOURNAL. LIMITED TIME OFFER 2 MONTHS FOR JUST US$1 BEST SALE OF THE YEAR ACT NOW
7:02 AM
2/12/2016

Surgeon Question

The FDA said the findings, in studies published online Monday by the New England Journal of Medicine, "have raised important questions about bioprosthetic aortic valves." Evidence suggests minuscule clots on the valves "may cause restricted motion," the agency said in a safety advisory. - WSJ October 5, 2015

Do you think this is a real is a real issue?

54% Answered Yes N=39

Meta Analysis Mechanical vs. Bioprosthetic Valves

Mechanical Versus Bioprosthetic Aortic Valve Replacement in Patients Aged 40 to 70 Years: A Systematic Review and Meta-Analysis

James J. Wu, BMusStudies, Michael Seco, BMedSc, MBBS,
James B. Edelman, MBBS(Hons), PhD, Guy D. Eslick, DrPH, PhD,
Michael K. Wilson, MBBS, FRACS, Michael P. Vallely, MBBS, PhD,
Michael J. Byrom, MBChB, PhD, and Paul G. Bannon, MBBS, PhD

Sydney Medical School, University of Sydney, Sydney; Baird Institute of Applied Heart and Lung Surgical Research, Sydney; Cardiothoracic Surgery Unit and Institute of Academic Surgery, Royal Prince Alfred Hospital, Sydney; Australian School of Advanced Medicine, Macquarie University, Sydney; and Whiteley-Martin Research Centre, Sydney, Australia

Review of 893 Studies
13 Selected for Analysis
4,287 Mechanical Valves vs. 4,259 Bioprosthetic Valves

Surgeon Prioritized Criteria for Selecting Valve



Surgeon Question

Do the previously shown results of the Meta analysis prioritized by physician attributes ranking change the current paradigm in favor of On-X vs. tissue valves in patients <65?

56% Answered Yes N=39

Familiarity With Replacement Valve Manufacturers

Unaided Awareness
Total 120 | Base: all cardiac surgeons



Q11,12: Please list all of the aortic valve replacement manufacturers you are aware of.
Please rate how familiar you are with the following aortic valve replacement manufacturers.
Survey conducted April 2015
Base: All cardiac surgeons

Percentage of Hospitals Stocking Each Manufacturer

Mechanical Aortic Replacement Valves
Total 120 | Base: all cardiac surgeons



Q13: Does your hospital stock this manufacturer's aortic replacement valve?
Survey conducted April 2015
Base: All cardiac surgeons

Broadened Direct Sales and Global Distribution

Combination will create critical mass in global distribution channels with significant opportunities for cross-selling



New Products

PhotoFix™ Decellularized Bovine Pericardium

Novel photofixation process promotes crosslinking of internal collagen structure

Only truly glutaradehyde-free bovine pericardial patch

Handling characteristics similar to autologous pericardium



US Patch Market:

19,500 procedures

Market Size = $18M

11% CAGR



Clinical Effectiveness[1]

1. Kalangos *et al.*, W Journal for Ped and Congen Heart Surgery (2013)

Note: Market procedures, share, size, and CAGR are approximate annual U.S. numbers based on actual CryoLife data and market reports, including LSI, iData and IMS.

Enhanced Cross-selling Opportunities

Combination will create critical mass in global distribution channels with significant opportunities for cross-selling



Strategic Focus on Aortic and Mitral Valve Surgery

Combination of CryoLife and On-X creates a highly differentiated product portfolio with a strategic focus on aortic and mitral valve repair and replacement surgery

Indication Expansion

PerClot® US IDE Trial

- **Adjunct hemostatic device to control capillary, venular, and arteriolar bleeding**
- **Methods**
  - + Prospective, multicenter, randomized, controlled vs. Bard Arista™
  - + Non-inferior hemostasis at 7 minutes
  - + Bleeding assessed using an objective, validated model
  - + 324 eligible subjects across 15 centers
    - Cardiac, General, and Urological
    - 108 patients per arm
    - 3 month follow-up for most procedures
- **Goal is to complete enrollment in 2016 or 2017 and FDA approval in 2019**

Bruckner B. and Loebe M. (2012)

Active Business Development Program

- ✓ Physician preference products
- ✓ Higher growth rate than CRY
- ✓ Higher margin than CRY
- ✓ Competitive advantage in market
- ✓ Synergistic to CRY

Anticipated Financial Benefits

- Acceleration of revenue growth through acquired products, channel expansion and cross-selling opportunities
- On-X product portfolio revenues projected to grow at double digit CAGR from 2016 – 2020
- Gross margin expansion
- Double digit CAGR in adjusted non-GAAP earnings from 2016 – 2020
- Future opportunities to invest in the operations of the business

2016 Guidance Summary

	February 15, 2016
Total Revenues	$178M- $180M Mid-single digits % pro-forma increase over 2015
Product revenues	Mid-single digits % pro-forma increase over 2015
Tissue processing revenues	Mid-single digit s % increase over 2015
Gross margins	Approximately 63%
R&D expenses	$13.0M - $15.0M
Non-GAAP adjusted income per common share	$0.29 - $0.32